Yoon‐Koo Kang
Impact in
- Gastroenterology top 0.02%
- Gastrointestinal Tumor Research and Treatment
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Gastric Cancer Management and Outcomes 277
- Metastasis and carcinoma case studies 57
- Oncology 269
- Colorectal Cancer Treatments and Studies 127
- Cancer Immunotherapy and Biomarkers 49
- Co-authors
- Eric Van Cutsem (21 shared papers)Hyun Cheol Chung (39 shared papers)Atsushi Ohtsu (17 shared papers)Min‐Hee Ryu (206 shared papers)Akira Sawaki (10 shared papers)Yung‐Jue Bang (32 shared papers)Florian Lordick (14 shared papers)Lin Shen (13 shared papers)
- Journals
- Journal of Clinical Oncology (167 papers)Annals of Oncology (51 papers)Gastric Cancer (28 papers)Cancer Chemotherapy and Pharmacology (25 papers)Cancer Research and Treatment (18 papers)
- Partner nations
- South KoreaUnited StatesJapan
In The Last Decade
Yoon‐Koo Kang
529 papers receiving 25.7k citations
Yoon‐Koo Kang's Hit Papers
Peers
Comparison fields: 5 of 154
- Gastroenterology 6.0k
- Hepatology 4.2k
- Oncology 12.3k
- Pulmonary and Respiratory Medicine 13.6k
- Pathology and Forensic Medicine 3.8k
Countries citing papers authored by Yoon‐Koo Kang
This map shows the geographic impact of Yoon‐Koo Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoon‐Koo Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoon‐Koo Kang more than expected).
Fields of papers citing papers by Yoon‐Koo Kang
This network shows the impact of papers produced by Yoon‐Koo Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoon‐Koo Kang. The network helps show where Yoon‐Koo Kang may publish in the future.
Co-authors
The 25 scholars most cited alongside Yoon‐Koo Kang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 550 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2010 | 5261 |
| 2 | Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Hit paper breakdown → | 2011 | 845 |
| 3 | Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Hit paper breakdown → | 2016 | 682 |
| 4 | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Hit paper breakdown → | 2013 | 621 |
| 5 | Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization Hit paper breakdown → | 1997 | 594 |
| 6 | Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial Hit paper breakdown → | 2013 | 586 |
| 7 | Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Hit paper breakdown → | 2009 | 582 |
| 8 | Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial Hit paper breakdown → | 2014 | 465 |
| 9 | Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib Hit paper breakdown → | 2014 | 449 |
| 10 | SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2014 | 438 |
| 11 | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study Hit paper breakdown → | 2017 | 391 |
| 12 | Management of gastric cancer in Asia: resource-stratified guidelines Hit paper breakdown → | 2013 | 384 |
| 13 | 2012 | 358 | |
| 14 | Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 342 |
| 15 | Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study Hit paper breakdown → | 2018 | 336 |
| 16 | The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines Hit paper breakdown → | 2015 | 310 |
| 17 | 1993 | 303 | |
| 18 | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Hit paper breakdown → | 2022 | 259 |
| 19 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) Hit paper breakdown → | 2018 | 228 |
| 20 | 2012 | 222 |
About Yoon‐Koo Kang
Yoon‐Koo Kang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Gastroenterology, Surgery and Hepatology, having authored 550 papers that have together received 26.2k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (277 papers), Gastrointestinal Tumor Research and Treatment (180 papers), Colorectal Cancer Treatments and Studies (127 papers), Hepatocellular Carcinoma Treatment and Prognosis (67 papers), Metastasis and carcinoma case studies (57 papers), Gastrointestinal disorders and treatments (50 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (48 papers). The work is most often cited by research in Gastroenterology (6.0k citations), Hepatology (4.2k citations), Oncology (12.3k citations), Pulmonary and Respiratory Medicine (13.6k citations) and Pathology and Forensic Medicine (3.8k citations). Yoon‐Koo Kang has collaborated with scholars based in South Korea, United States and Japan. Frequent co-authors include Eric Van Cutsem, Hyun Cheol Chung, Atsushi Ohtsu, Min‐Hee Ryu, Akira Sawaki, Yung‐Jue Bang, Florian Lordick, Lin Shen, Julie Hill and Michaela Lehle. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Gastric Cancer, Cancer Chemotherapy and Pharmacology and Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.